These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 28298024)

  • 1. Reduction of inflammation after administration of interleukin-1 receptor antagonist following aneurysmal subarachnoid hemorrhage: results of the Subcutaneous Interleukin-1Ra in SAH (SCIL-SAH) study.
    Galea J; Ogungbenro K; Hulme S; Patel H; Scarth S; Hoadley M; Illingworth K; McMahon CJ; Tzerakis N; King AT; Vail A; Hopkins SJ; Rothwell N; Tyrrell P
    J Neurosurg; 2018 Feb; 128(2):515-523. PubMed ID: 28298024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke): A Randomized Controlled Phase 2 Trial.
    Smith CJ; Hulme S; Vail A; Heal C; Parry-Jones AR; Scarth S; Hopkins K; Hoadley M; Allan SM; Rothwell NJ; Hopkins SJ; Tyrrell PJ
    Stroke; 2018 May; 49(5):1210-1216. PubMed ID: 29567761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial.
    Singh N; Hopkins SJ; Hulme S; Galea JP; Hoadley M; Vail A; Hutchinson PJ; Grainger S; Rothwell NJ; King AT; Tyrrell PJ
    J Neuroinflammation; 2014 Jan; 11():1. PubMed ID: 24383930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study.
    Morton AC; Rothman AM; Greenwood JP; Gunn J; Chase A; Clarke B; Hall AS; Fox K; Foley C; Banya W; Wang D; Flather MD; Crossman DC
    Eur Heart J; 2015 Feb; 36(6):377-84. PubMed ID: 25079365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation as a predictor for delayed cerebral ischemia after aneurysmal subarachnoid haemorrhage.
    McMahon CJ; Hopkins S; Vail A; King AT; Smith D; Illingworth KJ; Clark S; Rothwell NJ; Tyrrell PJ
    J Neurointerv Surg; 2013 Nov; 5(6):512-7. PubMed ID: 22952245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neopterin plasma concentrations in patients with aneurysmal subarachnoid hemorrhage: correlation with infection and long-term outcome.
    Azurmendi L; Degos V; Tiberti N; Kapandji N; Sanchez-Peña P; Sarrafzadeh A; Puybasset L; Turck N; Sanchez JC
    J Neurosurg; 2016 May; 124(5):1287-99. PubMed ID: 26406798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between inflammatory response and outcome after subarachnoid haemorrhage.
    Bjerkne Wenneberg S; Odenstedt Hergès H; Svedin P; Mallard C; Karlsson T; Adiels M; Naredi S; Block L
    Acta Neurol Scand; 2021 Feb; 143(2):195-205. PubMed ID: 32990943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated Systemic IL-6 Levels in Patients with Aneurysmal Subarachnoid Hemorrhage Is an Unspecific Marker for Post-SAH Complications.
    Chaudhry SR; Stoffel-Wagner B; Kinfe TM; Güresir E; Vatter H; Dietrich D; Lamprecht A; Muhammad S
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29194369
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage.
    Gueorguieva I; Clark SR; McMahon CJ; Scarth S; Rothwell NJ; Tyrrell PJ; Hopkins SJ; Rowland M
    Br J Clin Pharmacol; 2008 Mar; 65(3):317-25. PubMed ID: 17875190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of distance and transport method on intervention and mortality in aneurysmal subarachnoid hemorrhage.
    Weyhenmeyer J; Guandique CF; Leibold A; Lehnert S; Parish J; Han W; Tuchek C; Pandya J; Leipzig T; Payner T; DeNardo A; Scott J; Cohen-Gadol AA
    J Neurosurg; 2018 Feb; 128(2):490-498. PubMed ID: 28186453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of decompressive craniectomy on functional outcomes and death in poor-grade aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.
    Alotaibi NM; Elkarim GA; Samuel N; Ayling OGS; Guha D; Fallah A; Aldakkan A; Jaja BNR; de Oliveira Manoel AL; Ibrahim GM; Macdonald RL
    J Neurosurg; 2017 Dec; 127(6):1315-1325. PubMed ID: 28059660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients.
    Endo H; Hagihara Y; Kimura N; Takizawa K; Niizuma K; Togo O; Tominaga T
    J Neurosurg; 2022 Dec; 137(6):1707-1717. PubMed ID: 35364589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-1 receptor antagonist is beneficial after subarachnoid haemorrhage in rat by blocking haem-driven inflammatory pathology.
    Greenhalgh AD; Brough D; Robinson EM; Girard S; Rothwell NJ; Allan SM
    Dis Model Mech; 2012 Nov; 5(6):823-33. PubMed ID: 22679224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of premorbid hypertension and neurological status in aneurysmal subarachnoid hemorrhage: pooled analyses of individual patient data in the SAHIT repository.
    Jaja BN; Lingsma H; Schweizer TA; Thorpe KE; Steyerberg EW; Macdonald RL;
    J Neurosurg; 2015 Mar; 122(3):644-52. PubMed ID: 25554825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute impairment of saccadic eye movements is associated with delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.
    Rowland MJ; Garry P; Westbrook J; Corkill R; Antoniades CA; Pattinson KTS
    J Neurosurg; 2017 Oct; 127(4):754-760. PubMed ID: 27935361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Trial Protocol: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Subarachnoid Hemorrhage [NEWTON-2 (Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After SubarachNoid Hemorrhage)].
    Hänggi D; Etminan N; Mayer SA; Aldrich EF; Diringer MN; Schmutzhard E; Faleck HJ; Ng D; Saville BR; Macdonald RL;
    Neurocrit Care; 2019 Feb; 30(1):88-97. PubMed ID: 30014184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations.
    Clark SR; McMahon CJ; Gueorguieva I; Rowland M; Scarth S; Georgiou R; Tyrrell PJ; Hopkins SJ; Rothwell NJ
    J Cereb Blood Flow Metab; 2008 Feb; 28(2):387-94. PubMed ID: 17684519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative and postoperative predictors of long-term outcome after endovascular treatment of poor-grade aneurysmal subarachnoid hemorrhage.
    Zhao B; Yang H; Zheng K; Li Z; Xiong Y; Tan X; Zhong M;
    J Neurosurg; 2017 Jun; 126(6):1764-1771. PubMed ID: 27367238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levels of Interleukin-1β, Interleukin-18, and Tumor Necrosis Factor-α in Cerebrospinal Fluid of Aneurysmal Subarachnoid Hemorrhage Patients May Be Predictors of Early Brain Injury and Clinical Prognosis.
    Lv SY; Wu Q; Liu JP; Shao J; Wen LL; Xue J; Zhang XS; Zhang QR; Zhang X
    World Neurosurg; 2018 Mar; 111():e362-e373. PubMed ID: 29277532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid interleukin-1 receptor antagonist and tumor necrosis factor-alpha following subarachnoid hemorrhage.
    Mathiesen T; Edner G; Ulfarsson E; Andersson B
    J Neurosurg; 1997 Aug; 87(2):215-20. PubMed ID: 9254084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.